Using Sacituzumab Govitecan and Other ADCs in Urothelial Cancers
Arlene O. Siefker-Radtke, MD, discusses the data seen with sacituzumab govitecan, an antibody-drug conjugate that targets TROP-2, which is expressed frequently in urothelial cancer cells.
Arlene O. Siefker-Radtke, MD, professor, department of genitourinary medical oncology, division of cancer medicine, The University of Texas MD Anderson Cancer Center, discusses the data seen with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) that targets TROP-2, which is expressed frequently in urothelial cancer cells.
Response rates were around 30% with this agent, but it was associated with toxicites, says Siefker-Radtke. However, toxicities are common with other ADCs, such as enfortumab vedotin, which has a higher rate of neutropenia and neutropenic fevers.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
